BioLife Solutions, Inc. (NASDAQ:BLFS - Get Free Report) EVP Aby J. Mathew sold 7,604 shares of the firm's stock in a transaction on Monday, December 16th. The shares were sold at an average price of $27.33, for a total value of $207,817.32. Following the completion of the sale, the executive vice president now owns 276,315 shares in the company, valued at $7,551,688.95. The trade was a 2.68 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link.
BioLife Solutions Price Performance
BLFS traded up $1.13 during trading on Thursday, reaching $26.11. The stock had a trading volume of 404,267 shares, compared to its average volume of 384,028. The stock has a 50 day moving average of $24.78 and a two-hundred day moving average of $23.66. The company has a quick ratio of 1.78, a current ratio of 2.78 and a debt-to-equity ratio of 0.03. The firm has a market capitalization of $1.21 billion, a price-to-earnings ratio of -24.63 and a beta of 1.91. BioLife Solutions, Inc. has a 1-year low of $14.50 and a 1-year high of $28.88.
Institutional Trading of BioLife Solutions
Hedge funds and other institutional investors have recently modified their holdings of the company. Stifel Financial Corp raised its position in BioLife Solutions by 5.4% during the third quarter. Stifel Financial Corp now owns 12,988 shares of the medical equipment provider's stock valued at $325,000 after acquiring an additional 670 shares in the last quarter. Louisiana State Employees Retirement System raised its holdings in shares of BioLife Solutions by 4.0% during the 2nd quarter. Louisiana State Employees Retirement System now owns 18,300 shares of the medical equipment provider's stock valued at $392,000 after purchasing an additional 700 shares in the last quarter. GAMMA Investing LLC lifted its stake in shares of BioLife Solutions by 29.4% in the 3rd quarter. GAMMA Investing LLC now owns 3,295 shares of the medical equipment provider's stock valued at $83,000 after purchasing an additional 748 shares during the last quarter. The Manufacturers Life Insurance Company boosted its holdings in BioLife Solutions by 5.8% in the second quarter. The Manufacturers Life Insurance Company now owns 13,825 shares of the medical equipment provider's stock worth $296,000 after purchasing an additional 753 shares in the last quarter. Finally, Mark Sheptoff Financial Planning LLC bought a new position in BioLife Solutions during the third quarter valued at about $28,000. Institutional investors own 93.24% of the company's stock.
Analyst Ratings Changes
BLFS has been the topic of several recent research reports. Benchmark reiterated a "buy" rating and issued a $30.00 price objective on shares of BioLife Solutions in a research report on Thursday. HC Wainwright cut their price target on BioLife Solutions from $29.00 to $27.00 and set a "buy" rating on the stock in a report on Monday, November 18th. Craig Hallum boosted their price objective on BioLife Solutions from $30.00 to $32.00 and gave the stock a "buy" rating in a research report on Wednesday, November 13th. TD Cowen raised their target price on BioLife Solutions from $28.00 to $31.00 and gave the company a "buy" rating in a research report on Wednesday, November 13th. Finally, KeyCorp boosted their price target on BioLife Solutions from $30.00 to $33.00 and gave the stock an "overweight" rating in a research report on Friday, December 13th. One research analyst has rated the stock with a sell rating and seven have issued a buy rating to the company's stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and a consensus price target of $29.00.
View Our Latest Stock Report on BioLife Solutions
BioLife Solutions Company Profile
(
Get Free Report)
BioLife Solutions, Inc develops, manufactures, and markets bioproduction tools and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. The company's products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies.
Further Reading
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider BioLife Solutions, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and BioLife Solutions wasn't on the list.
While BioLife Solutions currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Thinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
